Figure 3.

Cardiac-specific overexpression of ADAR2 improves cardiac function in cardiac remodeling after MI

(A) The schedule of virus injection and MI remodeling model establishment. (B) Echocardiography of mice treated with AAV9-cTnT-ADAR2 with or without MI surgery (n = 8:10:8:11, ∗p < 0.05, ∗∗p < 0.01). LVID;s, left ventricular internal diameters of systole. (C) Heart weight/body weight (HW/BW) was calculated to evaluate cardiac adaptation in response to MI remodeling in control and ADAR2 overexpression mice (n = 8:10:8:11, ∗p < 0.05, ∗∗p < 0.01). (D) Masson trichrome staining of the hearts treated with AAV9-cTnT-ADAR2 followed by MI surgery, n = 8:10:8:11; scale bar, 100 μm (∗∗p < 0.01). (E) Quantitative real-time PCR analyzing the fibrotic factors (Ctgf, Col1a1, and Col3a1) in the hearts treated with AAV9-cTnT-ADAR2 followed by MI remodeling (n = 8:9:7:10, ∗∗p < 0.01).